Please wait while we load the requested 10-Q report or click the link below:
Prioritized head-to-head superiority clinical trial of SEL-212 compared to Krystexxa, expected to begin in the first quarter of 2019 as part of overall planned Phase 3 clinical development program and commercialization strategy
Potential for re-dosing of AAV gene therapy with SVP-Rapamycin platform to be explored in anticipated new clinical trial to start in 2H 2019
Newly appointed President and Chief Executive Officer, Carsten Brunn, Ph.D., to start December 1, 2018
Company to host conference call today at 8:30 a.m. ET
SEL-212 6-Month Head-to-Head Trial vs. Krystexxa Expected to Begin in 1Q 2019: Selecta plans to start a head-to-head superiority trial of SEL-212 compared to the current FDA-approved uricase therapy, Krystexxa, in the first quarter of 2019. Selecta expects to report interim data at the 3-month and 6-month timepoints in 2019 with full data anticipated in the first quarter of 2020.
Presented New Interim Phase 2 Clinical Data from Patients Receiving 5-Monthly Doses of SEL-212 at ACR 2018: At the 2018 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting in Chicago, Selecta presented interim data from new cohorts of patients that received five monthly doses of SEL-212 for the
The following information was filed by Selecta Biosciences Inc (SELB) on Thursday, November 8, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Selecta Biosciences Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Selecta Biosciences Inc.